Weekly Roundup: Chr. Hansen delivers 2020/21 financial results, Armada Nutrition to grow manufacturing capacity

Related Articles

FormattedPicture

NUTRITION & HEALTH NEWS

Enzymes manufacturer Novozymes has forecasted an outlook of between 4% to 7% for the 2023 financial year, having ended 2022 strong with 11% sales growth in Q4 despite a... Read More

FormattedPicture

BUSINESS NEWS

Chr. Hansen details the connections between the gut-brain axis and Irritable Bowel Syndrome (IBS) as well as the ability of some probiotics, like the company’s... Read More

FormattedPicture

NUTRITION & HEALTH NEWS

NutritionInsight looks back at the biggest industry developments of the year. From the US infant formula shortage to rising inflation, it was a year filled with... Read More

FormattedPicture

BUSINESS NEWS

Enzymes manufacturer Novozymes has agreed to buy Chr. Hansen to expand in the nutrition industry. The merger resulted in a US$12.3 billion deal, writing history as the... Read More

FormattedPicture

BUSINESS NEWS

Bioscience players Novozymes and Chr. Hansen are merging in a deal that will result in the dissolution of the latter by the fourth quarter of 2023. The new company is... Read More

trans